The abstract is read at the publisher; the summary is JClub's.
Chemoresponsive triple-negative breast cancer PDX models show distinct transcriptional trajectories that diverge within one week of chemotherapy, with early cytokine and apoptotic pathway activation absent in chemoresistant models.
- Why it matters: Predicting chemoresistance in neoadjuvant chemotherapy for TNBC is a major clinical challenge, and early biomarkers that reflect treatment response are needed.
- What they did: Serial fine needle aspirations with RNA-sequencing were performed on chemoresponsive versus chemoresistant TNBC PDX models, and paired patient biopsies were analyzed before treatment and within four days of the first chemotherapy dose.
- The result: In chemoresponsive tumors, early cytokine upregulation coincided with myeloid-derived immune cell infiltration into the tumor bed within seven days, and patient biopsies showed inflammatory pathway upregulation in responders versus diminished activation in non-responders.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.